Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Experiences Lighter than Usual Trading Volume

0
23

Trading was light with 1,247K shares changing hands by the end of trading on Thursday. Overall, volume was down 78.08% under the stocks normal daily volume.

Traders are more bearish on shares of the company recently at least if you consider the motion in short interest. The company experienced a rise in short interest between July 31, 2017 and August 15, 2017 of 15.30%. Short interest increased 775,540 over that timeframe. Days to cover increased from 1.2 to 4.0 and the short interest percentage is 0.04% as of August 15.

Here is the rundown on market activity for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). EVP Julie O’neill sold 11,160 shares at an average price of $140.00 on August 28th. O’neill now owns $3,738,560 of stock as reported to the SEC.

Here are a few additional firms who have increased or decreased their stake in (ALXN). Rock Springs Capital Management Lp augmented its investment by buying 6,100 shares an increase of 1.3% from 03/31/2017 to 06/30/2017. Rock Springs Capital Management Lp owns 463,000 shares worth $56,333,000. The total value of its holdings increased 1.7%. Point72 Asset Management, L.p. expanded its holdings by buying 40,100 shares an increase of 25.1% in the quarter. Point72 Asset Management, L.p. now holds 200,000 shares with a value of $24,334,000. The value of the position overall is up by 25.5%.

Rhenman & Partners Asset Management Ab added to its ownership by buying 42,298 shares an increase of 37.9%. Rhenman & Partners Asset Management Ab claims 154,000 shares valued at $18,737,000. The total value of its holdings increased 38.4%. As of quarter end Sivik Global Healthcare LLC had bought 60,000 shares growing its holdings by 120.0%. The value of the investment in (ALXN) went from $6,062,000 to $13,384,000 a change of $7,322,000 for the reporting period.

On August 17 analysts at Evercore ISI Group began coverage of the stock setting a rating of “In-Line”. July 28 investment analysts at Leerink Swann maintained a company rating of “Outperform” but moved down the price target from $211.00 to $170.00.

On July 28 the stock rating was upgraded from “Perform” to “Outperform” by analysts at Oppenheimer. On May 25 the company was rated “Overweight” in a report from Morgan Stanley a boost from the previous “Equal-Weight” rating.

The company is up by 0.05% since yesterday’s close of $138.38. The stock is trading at $138.45 which is just over $132.60, the stock’s 50 day moving average and which is significantly above the 200 day moving average of $123.39. The 50 day moving average moved up $5.85 and the 200 day average went up by +12.21%.

The company’s P/E ratio is 60.04 and market capitalization is 30.90B. In the last earnings report the EPS was $2.31 and is expected to be $5.60 for the current year with 223,185,000 shares currently outstanding. Next quarter’s EPS is expected be $1.33 with next year’s EPS anticipated to be $6.99.

Alexion Pharmaceuticals, Inc., launched on January 28, 1992, is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Business’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Business’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous)..